HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

Ezetimibe associated with lower dementia risk, possibly by reducing amyloid injury

Louis Nervegna · Mar 16, 2026 · ♥ 3 reactions · 0 comments · original Facebook post
PCSK9, ezetimibe & newer drugsBrain health & dementia
AI summary & key facts

Louis shares a video and link to a paper reporting that ezetimibe lowers risk of Alzheimer's and related dementias and may reduce amyloid aggregation and its resulting brain injury.

Link to the full study that he is referencing in the video:

Paper · Aging Biol · 2024Ezetimibe Lowers Risk of Alzheimer's and Related Dementias over Sevenfold, Reducing Aggregation in Model Systems by Inhibiting 14-3-3G::Hexokinase Interaction.Numerous factors predispose to progression of cognitive impairment to Alzheimer's disease and related dementias (ADRD), most notably age, APOE(ε4) alleles, traumatic brain injury, heart disease, hypertension, obesity/diabetes, and Down's syndrome. Protein aggregation is diagnostic for neurodegenerative diseases, and may be causal through promotion of chronic neuroinflammation. We isolated aggregates from postmortem…pmc.ncbi.nlm.nih.gov

Research cited

Ezetimibe reduces risk of dementia.

The drug appears to reduce amyloid and the resulting brain injury that it causes.

#ezetimibeHD #dementiaHD #alzheimersHD

← newer: Osteoarthritis is partly metabolic, which is why GLP-1 drugsolder: Fact-check health claims with AI: a viral video on oatmeal v →